Aldeyra Therapeutics (ALDX) Short term Debt (2013 - 2026)

Aldeyra Therapeutics' Short term Debt history runs 13 years deep, the most recent figure standing at $15.3 million for Q1 2026.

• Quarterly Short term Debt changed N/A year-over-year to $15.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.3 million (changed N/A YoY) and the FY2025 annual result came in at $15.2 million, up 48509.05% from the prior year.
• Short term Debt was $15.3 million for Q1 2026 at Aldeyra Therapeutics, roughly flat from $15.2 million in the prior quarter.
• Across five years, Short term Debt topped out at $15.3 million in Q1 2026 and bottomed at $31372.0 in Q4 2024.
• A 5-year average of $9.7 million and a median of $13.5 million in 2023 frame the typical range for Short term Debt.
• Annual changes were most pronounced in 2024 — Short term Debt plunged 99.79% — and 2025, when it surged 48509.05%.
• Aldeyra Therapeutics' Short term Debt stood at $911763.0 in 2022, then surged by 1561.24% to $15.1 million in 2023, then plunged by 99.79% to $31372.0 in 2024, then jumped by 48509.05% to $15.2 million in 2025, then grew by 0.33% to $15.3 million in 2026.
• Business Quant data shows ALDX's Short term Debt at $15.3 million in Q1 2026, $15.2 million in Q4 2025, and $15.2 million in Q3 2025.